ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 15.0% in June

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totalling 370,000 shares, a decrease of 15.0% from the May 31st total of 435,100 shares. Approximately 3.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,140,000 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ABVC BioPharma stock. Chase Investment Counsel Corp acquired a new stake in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 178,377 shares of the company’s stock, valued at approximately $233,000. Chase Investment Counsel Corp owned about 1.69% of ABVC BioPharma as of its most recent SEC filing. Institutional investors and hedge funds own 11.38% of the company’s stock.

ABVC BioPharma Trading Up 5.0 %

Shares of ABVC stock opened at $0.77 on Friday. ABVC BioPharma has a 52-week low of $0.67 and a 52-week high of $6.87. The stock has a fifty day simple moving average of $0.98 and a two-hundred day simple moving average of $1.16.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings results on Friday, May 17th. The company reported ($0.40) earnings per share (EPS) for the quarter. ABVC BioPharma had a negative return on equity of 207.72% and a negative net margin of 50,504.00%.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.